최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0439813 (2017-02-22) |
등록번호 | US-10258664 (2019-04-16) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 0 인용 특허 : 895 |
Methods and compositions for treating pain are disclosed. The compositions are based on dry powders comprising microparticles of diketopiperazines and an analgesic active agent. The analgesic in the compositions comprises one or more peptide analgesics or derivatives thereof, which are administered
Methods and compositions for treating pain are disclosed. The compositions are based on dry powders comprising microparticles of diketopiperazines and an analgesic active agent. The analgesic in the compositions comprises one or more peptide analgesics or derivatives thereof, which are administered to a subject using a pulmonary inhalation drug delivery system comprising a dry powder inhaler and the analgesic composition. The present compositions produce fewer side effects associated with current opioid therapy.
1. A method of reducing at least one of respiration depression, gastrointestinal distress, addiction, somnolescence, tolerance, nausea, and constipation in an opioid-dependent patient comprising reducing the opioid dosage amount while administering to the patient a composition comprising an inhalabl
1. A method of reducing at least one of respiration depression, gastrointestinal distress, addiction, somnolescence, tolerance, nausea, and constipation in an opioid-dependent patient comprising reducing the opioid dosage amount while administering to the patient a composition comprising an inhalable, analgesic composition comprising: microparticles of a diketopiperazine; and a peptide comprising less than 20 amino acids; wherein said composition is effective at relieving pain, and wherein the peptide is an opioid receptor agonist, and further wherein the peptide comprises at least one of: (D)Phe-(D)Phe-(D)Ile-(D)Arg-NH2 (SEQ ID NO: 1), (D)Phe-(D)Phe-(D)Nle-(D)Arg-NH2 (SEQ ID NO: 2), Trp-(D)Pro-Ser-Phe-NH2 (SEQ ID NO: 3), Trp-(D)Ser-Ser-Phe-NH2 (SEQ ID NO: 4); Dmt-D-Arg-Phe-Lys-NH2 (SEQ ID NO: 5), Ac-His-(D)Phe-Arg-(D)Trp-Gly-NH2 (SEQ ID NO: 6), and Ac-Nle-Gln-His-(D)Phe-Arg-(D)Trp-Gly-NH2 (SEQ ID NO:7). 2. The method of claim 1, wherein the composition is for pulmonary administration. 3. The method of claim 1, wherein the composition comprises a dry powder, and the peptide comprises at least 0.25% of the weight of the composition. 4. The method of claim 3, wherein the composition comprises a dry powder for inhalation and comprises microparticles having a volumetric mean geometric diameter less than 8 .mu.m in diameter. 5. The method of claim 4, wherein the diketopiperazine is an N-substituted-3,6-aminoalkyl-2,5-diketopiperazine. 6. The method of claim 5, wherein the diketopiperazine is 3,6-bis(N—X-4-aminobutyl)-2,5-diketopiperazine, wherein X is fumaryl, succinyl, glutaryl, maleyl, malonyl, oxalyl, or a pharmaceutically acceptable salt thereof. 7. The method of claim 6, wherein the diketopiperazine is 3,6-bis(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine, or 3,6-bis(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine disodium salt. 8. The method of claim 7, further comprising one or more pharmaceutical carrier or excipients selected from amino acids, sugars and surfactants. 9. The method of claim 8, wherein the sugars comprise at least one of mannitol, lactose, trehalose and raffinose. 10. The method of claim 9 wherein the peptide comprises SEQ ID NO: 1. 11. The method of claim 9 wherein the peptide comprises SEQ ID NO: 2. 12. The method of claim 9 wherein the peptide comprises SEQ ID NO: 3.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.